Citigroup
VIRX

Citigroup’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Citigroup’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-98
Closed -$143 – 5938
2022
Q4 		$143 Sell
98
-453
-82% -$1.32K ﹤0.01% 5622
2022
Q3 		$2K Sell
551
-495
-47% -$2.1K ﹤0.01% 5550
2022
Q2 		$4K Sell
1,046
-1,307
-56% -$3.72K ﹤0.01% 5728
2022
Q1 		$11K Sell
2,353
-7,784
-77% -$23.5K ﹤0.01% 5494
2021
Q4 		$37K Buy
10,137
+5,931
+141% +$31.6K ﹤0.01% 5207
2021
Q3 		$34K Buy
4,206
+2,199
+110% +$21.7K ﹤0.01% 4970
2021
Q2 		$23K Sell
2,007
-31,587
-94% -$317K ﹤0.01% 5231
2021
Q1 		$311K Buy
+33,594
New +$350K ﹤0.01% 3765
2016
Q2 		– Sell
-1
Closed -$111 – 7498
2016
Q1 		$0 Sell
1
-13
-93% -$1.97K ﹤0.01% 7823
2015
Q4 		$2K Buy
14
+8
+133% +$1.5K ﹤0.01% 7292
2015
Q3 		$1K Buy
+6
New +$2.17K ﹤0.01% 7238
2015
Q2 		– Sell
-59
Closed -$31.4K – 7797
2015
Q1 		$31K Buy
59
+12
+26% +$6.05K ﹤0.01% 5825
2014
Q4 		$26K Buy
47
+39
+488% +$17.6K ﹤0.01% 6091
2014
Q3 		$12K Sell
8
-2
-20% -$2.9K ﹤0.01% 6183
2014
Q2 		$14K Sell
10
-184
-95% -$213K ﹤0.01% 6019
2014
Q1 		$268K Buy
194
+110
+131% +$128K ﹤0.01% 4056
2013
Q4 		$84K Buy
84
+74
+740% +$76.5K ﹤0.01% 5376
2013
Q3 		$10K Buy
+10
New +$10.7K ﹤0.01% 6215
2013
Q2 		– Hold
0
– – – 6805

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Citigroup's VIRX Position: Q1 2023 in Review

Citigroup sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2023, closing a stake of 98 shares — an estimated $143 sold.

Citigroup first reported a position in VIRX in Q3 2013 and held it in 18 quarters. The position peaked at $311K in Q1 2021. 48 funds tracked by Wall St. Rank hold VIRX as of Q1 2023.

  • Citigroup reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 98 Viracta Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $143.
  • Citigroup first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2013 and held it in 18 quarters.
  • Citigroup's Viracta Therapeutics, Inc. Common Stock position peaked at $311K in Q1 2021.
  • 48 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.